XM does not provide services to residents of the United States of America.
S
S

Sobi


News

Babcock International, Scout24 Kymmene Oyj

EUROPE RESEARCH ROUNDUP- Babcock International, Scout24 SE, UPM-Kymmene Oyj Nov 14 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Babcock International, Scout24 SE and UPM-Kymmene Oyj, on Thursday. HIGHLIGHTS * Babcock International BAB.L : Jefferies raises target price to 750p from 720p * Just Eat Takeaway.Com JETJ.L : HSBC raises target price to 1575p from 1430p * Scout24 SE G24n.DE : Berenberg raises target price to EUR 110 fro
A
A
A
B
B
C
C
C
E
I
L
N
R
S
V
W
A
A
E
I
U

Swedish Orphan Biovitrum Says Nomination Committee Of Company Proposes David Meek As New Chair Of Board Of Directors

BRIEF-Swedish Orphan Biovitrum Says Nomination Committee Of Company Proposes David Meek As New Chair Of Board Of Directors Nov 4 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : SWEDISH ORPHAN BIOVITRUM - NOMINATION COMMITTEE OF SWEDISH ORPHAN BIOVITRUM AB PROPOSES DAVID MEEK AS NEW CHAIR OF BOARD OF DIRECTORS Source text: ID:nWkr8QJtq8 Fu
S

Hellofresh, Maersk, Scout24

EUROPE RESEARCH ROUNDUP-Hellofresh, Maersk, Scout24 Nov 1 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Hellofresh, Maersk and Scout24 on Friday. HIGHLIGHTS * Hellofresh SE HFGG.DE : JP Morgan raises to overweight from neutral * Knorr Bremse AG KBX.DE : Exane BNP Paribas cuts to neutral from outperform * Maersk MAERSKb.CO : JP Morgan raises target price to DKK 9,000 from DKK 8,575 * Next Plc NXT.L : Citigroup raises target price
A
A
B
C
I
M
M
N
P
R
S
S
S
V
E

ABB, Barratt Redrow, Ti Fluid Systems

EUROPE RESEARCH ROUNDUP-ABB, Barratt Redrow, Ti Fluid Systems Oct 29 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including ABB, Barratt Redrow and Ti Fluid Systems, on Tuesday. HIGHLIGHTS * ABB Ltd ABBN.S : Goldman Sachs cuts to neutral from buy * Barratt Redrow Plc BTRW.L : JP Morgan raises target price to 600p from 560p * Intermediate Capital Group Plc ICGIN.L : Citigroup raises PT to 2610p from 2600p * Ti Fluid Systems TIFS.L : Jeffer
A
B
B
B
C
C
C
D
E
E
E
E
G
H
H
I
K
L
M
P
P
R
S
S
S
S
S
W
G
Y

SOBI Says All Secondary Endpoints Favoured Pegcetacoplan Treatment

BRIEF-SOBI Says All Secondary Endpoints Favoured Pegcetacoplan Treatment Oct 27 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : PIVOTAL VALIANT RESULTS PRESENTED AT KIDNEY WEEK SHOW PEGCETACOPLAN TREATMENT EFFECT IN PATIENTS WITH C3G / PRIMARY IC-MPGN SOBI - ALL SECONDARY ENDPOINTS FAVOURED PEGCETACOPLAN TREATMENT SOBI - SOBI TO SUBMIT MA
S

SOBI Updates 2024 Revenue Outlook

BRIEF-SOBI Updates 2024 Revenue Outlook Oct 24 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : 2024 OUTLOOK: REVENUE IS ANTICIPATED TO GROW BY A MID-TEENS PERCENTAGE AT CER (PREVIOUSLY LOW DOUBLE-DIGIT) 2024 ADJUSTED EBITA MARGIN OUTLOOK UNCHANGED Source text for Eikon: ID:nWkr7CXqSq Further company coverage: SOBIV.ST (Gdansk Newsroom)
S

Merck's RSV antibody for infants effective in reducing some types of infections in study (Oct 17)

CORRECTED-Merck's RSV antibody for infants effective in reducing some types of infections in study (Oct 17) Corrects headline, paragraph 1 and 2 in Oct. 17 story to show the drug reduced medically attended lower respiratory infections, not all lower respiratory infections Oct 17 (Reuters) - Merck MRK.N said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some types of respiratory syncytial virus (RSV)-associated infections in infants.
A
P
S
S

SOBI, Enable Injections Announce Development and Distribution Agreement

BRIEF-SOBI, Enable Injections Announce Development and Distribution Agreement Sept 12 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : SOBI® AND ENABLE INJECTIONS ANNOUNCE AGREEMENT TO DEVELOP AND DISTRIBUTE ASPAVELI® IN COMBINATION WITH ENFUSE® IN SOBI TERRITORIES Source text for Eikon: ID:nWkr4Gc1vJ Further company coverage: SOBIV.ST
S



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.